
PACS Stock Forecast & Price Target
PACS Analyst Ratings
Bulls say
PACS Group is benefiting from strong same-store execution, with 3Q26 SNF revenue up 6.4%, occupancy rising to 91.3%, and skilled mix improving to 29.5%, which helped drive revenue of $1.499 billion and adjusted EBITDA of $175.7 million. Its outlook is reinforced by expansion momentum, as the company has added more than 8K net beds, raised 2026 adjusted EBITDA guidance to $685 million-$695 million, and generated $211.2 million of CFFO and $178.7 million of FCF in 3Q26. Financial flexibility remains a major strength, supported by $707.4 million of liquidity, net leverage of just 0.2x, quality-linked payments, and improving controls expected to be fully remediated by year-end 2026.
Bears say
PACS Group is exposed to meaningful reimbursement and policy risk, as potential Medicaid funding reforms and the rising penetration of Medicare Advantage could pressure skilled nursing margins, reduce clinical staffing capacity, and lower reimbursement versus Medicare fee-for-service. Its heavy concentration in California adds geographic risk, since the state’s structurally higher occupancy and skilled mix can distort future KPI comparisons as the company expands beyond it. Although weaker industry margins could spur M&A, that upside may reflect distress among smaller operators rather than durable organic growth for PACS.
This aggregate rating is based on analysts' research of PACS Group, Inc. and is not a guaranteed prediction by Public.com or investment advice.
PACS Analyst Forecast & Price Prediction
Start investing in PACS
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About PACS Group, Inc. (PACS) Forecast
PACS Analyst Forecast & Price Prediction
Start investing in PACS
Order type
Buy in
Order amount
Est. shares
0 shares